MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$3.97
-0.04 (-1.00%)
Open$3.92
Previous Close$4.01
Day High$4.02
Day Low$3.76
52W High$8.59
52W Low$2.74
Volume—
Avg Volume2.26M
Market Cap386.90M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Sell
15 analysts
Price Target
+943.8% upside
Current
$3.97
$3.97
Target
$41.44
$41.44
$29.39
$41.44 avg
$63.29
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 874.35M | 819.29M | 74.53M |
| Net Income | -388,022,295 | -327,230,196 | -15,758,896 |
| Profit Margin | -44.4% | -42.2% | -21.1% |
| EBITDA | -353,662,574 | -314,823,318 | -16,042,014 |
| Free Cash Flow | — | — | -13,316,178 |
| Rev Growth | +6.7% | +6.7% | +5.3% |
| Debt/Equity | 0.33 | 0.33 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.55 | +0.40% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $409.22 | +4.08% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $519.07 | +1.63% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $811.01 | +1.61% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $253.98 | +3.95% | 40.0 | 32.33B |